Cargando…
Treatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering
The purpose of this study was to investigate, in vitro and in vivo, the suitability of chitosan (CHS) scaffolds produced by the net-shape-nonwoven (NSN) technology, for use as bone graft substitutes in a critical-size femoral bone defect in rats. For in vitro investigations, scaffolds made of CHS, m...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393398/ https://www.ncbi.nlm.nih.gov/pubmed/34440219 http://dx.doi.org/10.3390/biomedicines9081015 |
_version_ | 1783743718670467072 |
---|---|
author | Zwingenberger, Bruno Vater, Corina Bell, Roland L. Bolte, Julia Mehnert, Elisabeth Brünler, Ronny Aibibu, Dilbar Zwingenberger, Stefan |
author_facet | Zwingenberger, Bruno Vater, Corina Bell, Roland L. Bolte, Julia Mehnert, Elisabeth Brünler, Ronny Aibibu, Dilbar Zwingenberger, Stefan |
author_sort | Zwingenberger, Bruno |
collection | PubMed |
description | The purpose of this study was to investigate, in vitro and in vivo, the suitability of chitosan (CHS) scaffolds produced by the net-shape-nonwoven (NSN) technology, for use as bone graft substitutes in a critical-size femoral bone defect in rats. For in vitro investigations, scaffolds made of CHS, mineralized collagen (MCM), or human cancellous bone allograft (CBA) were seeded with human telomerase-immortalized mesenchymal stromal cells (hTERT-MSC), incubated for 14 days, and thereafter evaluated for proliferation and osteogenic differentiation. In vivo, CHS, MCM and CBA scaffolds were implanted into 5 mm critical-size femoral bone defects in rats. After 12 weeks, the volume of newly formed bone was determined by microcomputed tomography (µCT), while the degree of defect healing, as well as vascularization and the number of osteoblasts and osteoclasts, was evaluated histologically. In vitro, CHS scaffolds showed significantly higher osteogenic properties, whereas treatment with CHS, in vivo, led to a lower grade of bone-healing compared to CBA and MCM. While chitosan offers a completely new field of scaffold production by fibers, these scaffolds will have to be improved in the future, regarding mechanical stability and osteoconductivity. |
format | Online Article Text |
id | pubmed-8393398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83933982021-08-28 Treatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering Zwingenberger, Bruno Vater, Corina Bell, Roland L. Bolte, Julia Mehnert, Elisabeth Brünler, Ronny Aibibu, Dilbar Zwingenberger, Stefan Biomedicines Article The purpose of this study was to investigate, in vitro and in vivo, the suitability of chitosan (CHS) scaffolds produced by the net-shape-nonwoven (NSN) technology, for use as bone graft substitutes in a critical-size femoral bone defect in rats. For in vitro investigations, scaffolds made of CHS, mineralized collagen (MCM), or human cancellous bone allograft (CBA) were seeded with human telomerase-immortalized mesenchymal stromal cells (hTERT-MSC), incubated for 14 days, and thereafter evaluated for proliferation and osteogenic differentiation. In vivo, CHS, MCM and CBA scaffolds were implanted into 5 mm critical-size femoral bone defects in rats. After 12 weeks, the volume of newly formed bone was determined by microcomputed tomography (µCT), while the degree of defect healing, as well as vascularization and the number of osteoblasts and osteoclasts, was evaluated histologically. In vitro, CHS scaffolds showed significantly higher osteogenic properties, whereas treatment with CHS, in vivo, led to a lower grade of bone-healing compared to CBA and MCM. While chitosan offers a completely new field of scaffold production by fibers, these scaffolds will have to be improved in the future, regarding mechanical stability and osteoconductivity. MDPI 2021-08-14 /pmc/articles/PMC8393398/ /pubmed/34440219 http://dx.doi.org/10.3390/biomedicines9081015 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zwingenberger, Bruno Vater, Corina Bell, Roland L. Bolte, Julia Mehnert, Elisabeth Brünler, Ronny Aibibu, Dilbar Zwingenberger, Stefan Treatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering |
title | Treatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering |
title_full | Treatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering |
title_fullStr | Treatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering |
title_full_unstemmed | Treatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering |
title_short | Treatment of Critical-Size Femoral Bone Defects with Chitosan Scaffolds Produced by a Novel Process from Textile Engineering |
title_sort | treatment of critical-size femoral bone defects with chitosan scaffolds produced by a novel process from textile engineering |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393398/ https://www.ncbi.nlm.nih.gov/pubmed/34440219 http://dx.doi.org/10.3390/biomedicines9081015 |
work_keys_str_mv | AT zwingenbergerbruno treatmentofcriticalsizefemoralbonedefectswithchitosanscaffoldsproducedbyanovelprocessfromtextileengineering AT vatercorina treatmentofcriticalsizefemoralbonedefectswithchitosanscaffoldsproducedbyanovelprocessfromtextileengineering AT bellrolandl treatmentofcriticalsizefemoralbonedefectswithchitosanscaffoldsproducedbyanovelprocessfromtextileengineering AT boltejulia treatmentofcriticalsizefemoralbonedefectswithchitosanscaffoldsproducedbyanovelprocessfromtextileengineering AT mehnertelisabeth treatmentofcriticalsizefemoralbonedefectswithchitosanscaffoldsproducedbyanovelprocessfromtextileengineering AT brunlerronny treatmentofcriticalsizefemoralbonedefectswithchitosanscaffoldsproducedbyanovelprocessfromtextileengineering AT aibibudilbar treatmentofcriticalsizefemoralbonedefectswithchitosanscaffoldsproducedbyanovelprocessfromtextileengineering AT zwingenbergerstefan treatmentofcriticalsizefemoralbonedefectswithchitosanscaffoldsproducedbyanovelprocessfromtextileengineering |